Local Anesthesia for TAVR Was Safe and Reduced Hospital Stays

A minimalist approach to transcatheter aortic valve replacement (TAVR) involving local anesthesia appears to have several advantages, according to this new meta-analysis.

 

In addition to shortening times for procedures and lengths of stay in the critical care unit and hospital, lighter sedation may lower the need for transfusions or treatment with inotropes or vasopressors.

 

Those benefits do not come with clinical complications. In fact, mortality at 30 days was lower in those receiving TAVR with local anesthesia (3.7% vs. 4.2%; risk ratio [RR]: 0.76; 95% confidence interval [CI]: 0.64-0.92).

 

In the earlier days of TAVR, procedures were typically performed under general anesthesia with orotracheal intubation. However, in time, accumulating evidence suggested that using local anesthesia in the procedure, as part of a minimalist approach, is not only feasible but also beneficial.

 

While the meta-analysis is not to be considered as definitive evidence as regards hard endpoints such as mortality, a minimalist strategy presents enough advantages to support its application.

 

This meta-analysis included 27 studies and a total of 24,085 patients.

 

Most procedural variables turned out to be similar for both strategies, including rates of stroke, acute myocardial infarction, renal failure, vascular complications, major bleeding, a need for a permanent pacemaker, paravalvular insufficiency, or fluoroscopy time.

 

Patients who received local anesthesia presented the following advantages:

  • a shorter average procedure time (90 vs. 127 minutes),
  • less time in the critical care unit (1.5 vs. 3.0 days),
  • less time in the hospital (5 vs 9 days),
  • possibly, lower mortality (although this conclusion might be biased).

 

Original title: Comparison of Local Versus General Anesthesia in Patients Undergoing Transcatheter Aortic Valve Replacement: A Meta-Analysis and Meta-Regression.

Presenter: Villablanca PA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...

TAVI and Hypertrophic Cardiomyopathy: An Increasingly Common Association

Stenosis is a common disease affecting 5% of the elderly population. It is associated with hospitalizations, poor quality of life, and mortality.  The association between...

TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients.  The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...